Clinical trials: Coronary Patient
Atrial Fibrillation, Atrial Flutter
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter
Double blind study to evaluate the efficacy and tolerability of SSR149744C and select a dose to be further investigated in the maintenance of sinus rhythm after electrical, pharmacological or spontaneous conversion of AF/AFL.
- Trial name
- MAIA (NCT00233441)
- Testing
- CELIVARONE (SSR149744C)
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 673 people
- Sponsor
- Sanofi
Cardiac Arrhythmias
Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter
The purpose of this study is a feasibility study for the Rhythmia Medical Mapping System and Mapping Catheter on patients undergoing catheter ablation procedures for the treatment of cardiac tachyarrhythmias.
- Trial name
- NCT01642537
- Testing
- Rhythmia Mapping System and the Rhythmia Mapping Catheter
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Boston Scientific Corporation
Stable Angina, Unstable Angina
Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease
To evaluate the safety and effectiveness of the ALEX stent in a real-world setting of percutaneous coronary interventions in patients with coronary heart disease.
- Conditions
- Stable Angina, Unstable Angina, Myocardial Infarction
- Trial name
- ALEX OCT (NCT01637012)
- Testing
- Implantation
- Where
- 5 sites in Poland
- Volunteers
- 60 people
- Sponsor
- Balton Sp.zo.o.
Heart Failure of Reduced Ejection Fraction (HFrEF)
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
- Trial name
- NCT07044700
- Testing
- Jardiance, non-SGLT2 inhibitors
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Hypertension, Resistant to Conventional Therapy, Atrioventricular Block
Moderato System in Patients With Hypertension
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a…
- Trial name
- NCT03757377
- Testing
- BackBeat Moderato System, BackBeat Moderato Sytsem
- Where
- 4 sites in Belgium, Lithuania and 1 more
- Volunteers
- 203 people
- Sponsor
- BackBeat Medical Inc
Atrial Fibrillation, Atrial Flutter
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
The primary purpose of this study is to optimize drug exposure in the target population.
- Trial name
- NCT01229254
- Testing
- Amiodarone, Betrixaban 60 mg, Betrixaban 90 mg
- Volunteers
- 189 people
- Sponsor
- Portola Pharmaceuticals
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease.
- Trial name
- NCT06809686
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Richmond Research Institute
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Heart Failure
Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
This study is designed to understand the pharmacokinetics of different oral formulations of CK-1827452 being considered for future studies in patients with heart failure.
- Trial name
- NCT00941681
- Testing
- CK-1827452
- Where
- 3 sites in Georgia
- Volunteers
- 35 people
- Sponsor
- Cytokinetics
Fluid Retention Caused by Heart Failure
Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention
Phase II clinical study of HRS-9057 injection in patients with heart failure-induced fluid retention
- Trial name
- NCT07318103
- Testing
- HRS-9057 injection set, 5% Glucose Injection or 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hypertension Resistant to Conventional Therapy, Bradycardia
Moderato System: A Double-Blind Randomized Trial Ver 1.1
The purpose of this double blind randomized study is the evaluation of the safety and efficacy of the Moderato System. The Moderato implantable pulse generator is indicated for patients who have hypertension and also require a…
- Conditions
- Hypertension Resistant to Conventional Therapy, Bradycardia, Atrioventricular Block
- Trial name
- NCT02837445
- Testing
- PHC ON, PHC OFF
- Where
- 12 sites in Austria, Belgium and 5 more
- Volunteers
- 70 people
- Sponsor
- BackBeat Medical Inc
Right Heart Failure
The Use of Impella RP Support System in Patients With Right Heart Failure
The use of Impella RP is safe, feasible and provides a hemodynamic benefit in patients with right ventricular failure.
- Trial name
- NCT01777607
- Testing
- IMPELLA® RP
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abiomed Inc.
Heterozygous Familial Hypercholesterolaemia
Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Eprotirome is a liver selective thyroid hormone that can reduce several independent risk factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- AKKA (NCT01410383)
- Testing
- Eprotirome
- Volunteers
- 236 people
- Sponsor
- Karo Bio AB
Atrial Fibrillation
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
- Trial name
- DIONYSOS (NCT00489736)
- Testing
- dronedarone (SR33589), amiodarone
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 504 people
- Sponsor
- Sanofi
Coronary Artery Disease, Cardiac Death
BioFreedom QCA Study in CAD Patients
This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.
- Conditions
- Coronary Artery Disease, Cardiac Death, Myocardial Infarction
- Trial name
- BioFreedomQCA (NCT03307213)
- Testing
- BioFreedom™ CoCr Biolimus A9™ stent, BioFreedom™ SS Biolimus A9™ stent
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 200 people
- Sponsor
- Biosensors Europe SA
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Hyponatremia, Acute Decompensated Heart Failure
Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)
This study will evaluate the safety and effectiveness of Conivaptan, a vasopressin antagonist, in the treatment of hyponatremic subjects having symptomatic acute decompensated heart failure (ADHF).
- Trial name
- CONVERT-H (NCT00843986)
- Testing
- conivaptan
- Where
- 4 sites in India
- Volunteers
- 9 people
- Sponsor
- Cumberland Pharmaceuticals
Obstructive Hypertrophic Cardiomyopathy
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
- Trial name
- COMPASS-HCM (NCT06551129)
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Bristol-Myers Squibb